⁶⁸Ga-PSMA-PET/CT-directed IGRT/SBRT for oligometastases of recurrent prostate cancer after initial surgery

References

• NCCN Guidelines® & Clinical Resources [Internet]. Pennsylvania (US): National Comprehensive Cancer Network; 2019. [cited Aug 12]. Available from: www.nccn.org
   Google Scholar
• Interdisziplinäre Leitlinie der Qualität S3 zur Früherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms Version 5.0 [German S3-Guideline] [Internet] Berlin (DE): Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF; 2019. [cited Aug 12]. Available from: www.leitlinienprogramm-onkologie.de
   Google Scholar
• Cornford P, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: Treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol. 2017;71(4):630–642.
   PubMed Web of Science ®Google Scholar
• Hellman S, Weichselbaum RR. Oligometastases. JCO. 1995;13(1):8–10.
   PubMed Web of Science ®Google Scholar
• Tree AC, Khoo VS, Eeles RA, et al. Stereotactic body radiotherapy for oligometastases. Lancet Oncol. 2013;14(1):e28–e37.
   PubMed Web of Science ®Google Scholar
• Gillessen S, Attard G, Beer TM, et al. Management of patients with advanced prostate cancer: the report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. Eur Urol. 2018;73(2):178–211.
   PubMed Web of Science ®Google Scholar
• Bluemel C, Linke F, Herrmann K, et al. Impact of (68)Ga-PSMA PET/CT on salvage radiotherapy planning in patients with prostate cancer and persisting PSA values or biochemical relapse after prostatectomy. EJNMMI Res. 2016;6(1):78.
   PubMed Web of Science ®Google Scholar
• Palacios-Eito A, Bejar-Luque A, Rodriguez-Linan M, et al. Oligometastases in prostate cancer: ablative treatment. WJCO. 2019;10(2):38–51.
   Web of Science ®Google Scholar
• Ost P, Jereczek-Fossa BA, As NV, et al. Progression-free survival following stereotactic body radiotherapy for oligometastatic prostate cancer treatment-naive recurrence: a multi-institutional analysis. Eur Urol. 2016;69(1):9–12.
   PubMed Web of Science ®Google Scholar
• Siva S, Bressel M, Murphy DG, et al. Stereotactic Abative Body Radiotherapy (SABR) for oligometastatic prostate cancer: a prospective clinical trial. Eur Urol. 2018;74(4):455–462.
   PubMed Web of Science ®Google Scholar
• Kneebone A, Hruby G, Ainsworth H, et al. Stereotactic body radiotherapy for oligometastatic prostate cancer detected via prostate-specific membrane antigen positron emission tomography. Eur Urol Oncol. 2018;1(6):531–537.
   PubMed Web of Science ®Google Scholar
• Incerti E, Gangemi V, Mapelli P, et al. 11C-Choline PET/CT based helical tomotherapy as treatment approach for bone metastases in recurrent prostate cancer patients. Curr Radiopharm. 2017;10(3):195–202.
   PubMed Web of Science ®Google Scholar
• Ost P, Reynders D, Decaestecker K, et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. JCO. 2018;36(5):446–453.
   PubMed Web of Science ®Google Scholar
• Schwenck J, Rempp H, Reischl G, et al. Comparison of (68)Ga-labelled PSMA-11 and (11)C-choline in the detection of prostate cancer metastases by PET/CT. Eur J Nucl Med Mol Imaging. 2017;44(1):92–101.
   PubMed Web of Science ®Google Scholar
• Ghadjar P, Hayoz S, Bernhard J, et al. Impact of dose intensified salvage radiation therapy on urinary continence recovery after radical prostatectomy: results of the randomized trial SAKK 09/10. Radiother Oncol. 2018;126(2):257–262.
   PubMed Web of Science ®Google Scholar
• Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31(5):1341–1346.
   PubMed Web of Science ®Google Scholar
• Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03. National Institutes of Health National Cancer Institute; 2010.
   Google Scholar
• Bolla M, van Poppel H, Collette L, et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet. 2005;366(9485):572.
   PubMed Web of Science ®Google Scholar
• Roach M, Hanks G, Thames H, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol. 2006;65(4):965–974.
   PubMed Web of Science ®Google Scholar
• Consensus statement: guidelines for PSA following radiation therapy. American Society for therapeutic radiology and oncology consensus panel. Int J Radiat Oncol Biol Phys. 1997;37(5):1035–1041.
   PubMed Web of Science ®Google Scholar
• Schwenck J, Olthof S, Pfannenberg C, et al. Intention to treat analysis of 68Ga-PSMA and 11C-choline PET/CT versus CT for prostate cancer recurrences after surgery. J Nucl Med. [cited 2019 Mar 8]. DOI:10.2967/jnumed.118.224543.
   PubMed Web of Science ®Google Scholar
• Perera M, Papa N, Christidis D, et al. Sensitivity, specificity, and predictors of positive (68)Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis. Eur Urol. 2016;70(6):926–937.
   PubMed Web of Science ®Google Scholar
• Evangelista L, Briganti A, Fanti S, et al. New clinical indications for (18)F/(11)C-choline, new tracers for positron emission tomography and a promising hybrid device for prostate cancer staging: a systematic review of the literature. Eur Urol. 2016;70(1):161–175.
   PubMed Web of Science ®Google Scholar
• von Eyben FE, Picchio M, von Eyben R, et al. 68Ga-labeled prostate-specific membrane antigen ligand positron emission tomography/computed tomography for prostate cancer: a systematic review and meta-analysis. Eur Urol Focus. 2018;4:686–693.
   PubMedGoogle Scholar
• Herlemann A, Wenter V, Kretschmer A, et al. 68Ga-PSMA positron emission tomography/computed tomography provides accurate staging of lymph node regions prior to lymph node dissection in patients with prostate cancer. Eur Urol. 2016;70(4):553–557.
   PubMed Web of Science ®Google Scholar
• Budaus L, Leyh-Bannurah SR, Salomon G, et al. Initial experience of (68)Ga-PSMA PET/CT imaging in high-risk prostate cancer patients prior to radical prostatectomy. Eur Urol. 2016;69(3):393–396.
   PubMed Web of Science ®Google Scholar
• Gupta SK, Watson T, Denham J, et al. Prostate-specific membrane antigen positron emission tomography-computed tomography for prostate cancer: distribution of disease and implications for radiation therapy planning. Int J Radiat Oncol Biol Phys. 2017;99(3):701–709.
   PubMed Web of Science ®Google Scholar
• Rischpler C, Beck TI, Okamoto S, et al. 68Ga-PSMA-HBED-CC uptake in cervical, celiac, and sacral ganglia as an important pitfall in prostate cancer PET imaging. J Nucl Med. 2018;59(9):1406–1411.
   PubMed Web of Science ®Google Scholar
• Baumann R, Koncz M, Luetzen U, et al. Oligometastases in prostate cancer: metabolic response in follow-up PSMA-PET-CTs after hypofractionated IGRT. Strahlenther Onkol. 2018;194(4):318–324.
   PubMed Web of Science ®Google Scholar
• Bolla M, Verry C, Long JA. High-risk prostate cancer: combination of high-dose, high-precision radiotherapy and androgen deprivation therapy. Curr Opin Urol. 2013;23(4):349–354.
   PubMed Web of Science ®Google Scholar
• Da Pozzo LF, Cozzarini C, Briganti A, et al. Long-term follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy: the positive impact of adjuvant radiotherapy. Eur Urol. 2009;55(5):1003–1011.
   PubMed Web of Science ®Google Scholar
• Abdollah F, Karnes RJ, Suardi N, et al. Impact of adjuvant radiotherapy on survival of patients with node-positive prostate cancer. JCO. 2014;32(35):3939–3947.
   PubMed Web of Science ®Google Scholar
• Lin CC, Gray PJ, Jemal A, et al. Response. J Natl Cancer Inst. 2015;107(9):djv200.
   PubMedGoogle Scholar
• Radiotherapy of the prostate and the Pelvic Lymph Nodes After Neoadjuvant Antihormonal Treatment (PLATIN). Clinical Trials. gov Identifier NCT01903408; 2018.
   Google Scholar
• Percutaneous High-dose Radiotherapy in Patients with Oligometastases of Prostate Carcinoma (Oli-P). ClinicalTrials.gov Identifier: NCT02264379; 2018.
   Google Scholar
• Muller AC, Lutjens J, Alber M, et al. Toxicity and outcome of pelvic IMRT for node-positive prostate cancer. Strahlenther Onkol. 2012;188(11):982–989.
   PubMed Web of Science ®Google Scholar
• Henkenberens C, von Klot CA, Ross TL, et al. 68Ga-PSMA ligand PET/CT-based radiotherapy in locally recurrent and recurrent oligometastatic prostate cancer: early efficacy after primary therapy. Strahlenther Onkol. 2016;192(7):431–439.
   PubMed Web of Science ®Google Scholar